We sought to determine the frequency and timing of complications at our institution when surgery was performed within two months of coronary stent placement. BACKGROUND The optimal delay following coronary stent placement prior to non-cardiac surgery is unknown.
Stent thrombosis is a highly morbid complication of coronary stent placement. Most cases of stent thrombosis result in Q-wave myocardial infarction (MI) or death (1) (2) (3) (4) (5) (6) (7) . With the use of combined antiplatelet therapy after stent placement (aspirin and thienopyridine) the frequency of stent thrombosis is extremely low, generally Ͻ1%, and it usually occurs in the first few days following stent placement (1, 8, 9) . However, the impact of non-cardiac surgery on the frequency and timing of stent thrombosis is unclear. It follows, therefore, that the optimal delay following coronary stent placement prior to non-cardiac surgery is unknown. The only previous study addressing this issue reported a mortality rate of 32% among 40 patients when surgery was performed Յ2 weeks following stent placement; in that study, neither death, MI, nor stent thrombosis occurred when surgery was performed after a Ͼ2 week delay (10) . We examined the frequency and timing of complications at our institution when non-cardiac surgery was performed within two months of coronary stent placement.
METHODS
We performed a retrospective analysis of the Percutaneous Coronary Intervention database and the General Surgery database at Mayo Clinic and identified 207 patients who underwent non-cardiac surgery within 60 days of coronary stent placement. Surgical procedures included in this analysis were those that required a significant incision and had the potential for perioperative bleeding. Procedures such as joint aspirations, endoscopy, and skin biopsies, among others, were not included in this analysis. All patients undergoing percutaneous coronary revascularization at the Mayo Clinic are followed up according to a protocol approved by the Mayo Clinic Institutional Review Board. The Percutaneous Coronary Intervention database includes baseline and in-hospital demographic, clinical, and angiographic data. Definitions. Successful stent placement was defined as Ն20% reduction in the lumen diameter stenosis, resulting in a final residual stenosis within the stent of Ͻ50% by visual estimation, with achievement of Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 and without the in-laboratory occurrence of death, Q-wave MI, or requirement of coronary artery bypass graft (CABG) surgery (11) . A perioperative MI was considered to have occurred when at least two of the following three criteria were met: 1) chest pain Ͼ30 min; 2) persistent electrocardiographic (ECG) changes suggestive of ischemia; or 3) characteristic elevations in serum creatine kinase (CK) levels or CK-MB isoform (Ն2 times normal). Q-wave MI was defined as two of the above criteria with new pathologic Q waves in the coronary distribution of the stented artery. Thrombus was considered to be present when one or more lumen-filling defects in a coronary artery were visualized with contrast present on three sides. Dissections were diagnosed when contrast staining was apparent within the vessel wall, and they were classified according to the National Heart, Lung, and Blood Institute (NHLBI) classification system (12) . Single-vessel disease was defined as the presence of a Ն70% lesion in one of the three major coronary arteries or their major branches. Multivessel disease was defined as the presence of a Ն70% lesion in a major coronary artery or its major branches and a Ն50% lesion in a second coronary artery or its major branches. The angiographic severity of coronary artery stenoses was assessed visually using two orthogonal views. Lesions were classified according to the modified American Heart Association/American College of Cardiology lesion classification scheme by the interventional cardiologist performing the angioplasty procedure, immediately before the procedure was performed (13) . Using a modified Simpson's rule, left ventricular ejection fractions were calculated from ventriculography performed in a 30°r ight anterior oblique projection (14) . Intracoronary stent implantation technique. Coronary angioplasty and intracoronary stent implantation were performed using standard percutaneous techniques via the femoral, brachial, or radial artery. In the earlier time period, 8F guide catheters and over-the-wire systems were utilized. In the more recent study period, rapid-exchange systems and 6F and 7F guide catheters were more commonly used. Intravascular ultrasound was used infrequently (Ͻ10%), at the discretion of the operator. Medical therapy. All patients received pre-procedural oral aspirin (325 mg) and intravenous heparin to achieve an activated clotting time of approximately 300 s, or approximately 250 s if a platelet glycoprotein IIb/IIIa inhibitor was used. In patients receiving a combination of warfarin and aspirin, warfarin was initiated the evening of the procedure and intravenous heparin was continued until the International Normalized Ratio (INR) was Ն2.0. In patients receiving ticlopidine (which became routine in early 1995), the first dose was administered before the procedure (generally within 1 h), with an initial loading dose of 500 mg, and a 250-mg dose was administered later that evening followed by 250 mg twice a day for two to four weeks, in addition to aspirin 81 to 325 mg daily. After March 1998, clopidogrel was substituted for ticlopidine and was given as a loading dose of 300 mg either immediately before or during the procedure, followed by 75 mg daily for two to four weeks. Bleeding complications. The hospital charts of all patients included in the study were reviewed; only bleeding data from three charts (1.4%) were unavailable for review. The following data were collected from the surgical, anesthesia, nursing, and physician's notes and reports: date of percutaneous coronary intervention and surgery, type of surgery, interval between last dose of antiplatelet agent (aspirin and thienopyridine) and warfarin (and INR level), surgical procedure, estimated blood loss, presence of excessive surgical bleeding (defined as persistent bleeding despite adequate use of electrocautery and suture, or decreased clotting time within the surgical field), and perioperative transfusion requirements. End points. The frequency of death, Q-wave MI, non-Qwave MI, stent thrombosis, surgical bleeding complications, and repeat revascularization with either CABG or repeat angioplasty of the target vessel were analyzed. The earliest and latest dates that patients in this study received stents were July 31, 1990 
RESULTS

Baseline characteristics.
The 207 patients included in this study underwent surgery 1 to 60 days following stent implantation. The baseline clinical and postprocedural angiographic characteristics of all 207 patients in the study population, and of patients grouped into those who did (n ϭ 8) and did not (n ϭ 199) suffer a major adverse event, are summarized in Table 1 . Adjunctive medical therapy. The medical therapies received at discharge (Table 2) did not differ between patients who did and did not suffer an adverse event after noncardiac surgery. Only 21% of patients (n ϭ 43) were discharged while receiving warfarin; 75% of patients (n ϭ 155) were discharged while receiving aspirin and a thienopyridine.
Procedural characteristics. The procedural characteristics of the revascularization procedure are displayed in Tables 3  and 4 . Patients who suffered a major adverse event had a significantly more severe residual stenosis (17 Ϯ 17% vs. 9 Ϯ 17%, p ϭ 0.04) than those who did not have an event. Surgical procedures. Types of surgical procedures are listed in Table 5 . Most patients in the study underwent vascular surgery. None of the patients who underwent genitourinary, head and neck, or breast surgery in this study suffered a major adverse event, although the number of such patients was relatively small. Adverse events. Eight of 207 patients had major adverse cardiac events. Of these, six patients died, two of whom suffered or were suffering an MI before dying (Table 6) . One patient had a non-fatal MI. The percentage of patients suffering a major adverse event and the number of weeks that surgery was performed after stent placement are displayed in Figure 1 . Bleeding complications from surgery. At the time of surgery, 54 patients (26%) received both aspirin and thienopyridine, 29 patients (14%) received aspirin and had received the last dose of thienopyridine within the previous 10 days, 104 patients (51%) received aspirin only, 13 
patients (6.3%) received no antiplatelet agents, and 4 patients (2.0%) received aspirin and warfarin, all of whom had an INR Ն1.7 (Table 7) . Only two patients were described by either the surgeon or the anesthesiologist as having excessive bleeding during surgery; one patient received both aspirin and ticlopidine, and the second patient received aspirin alone. None of the four patients with an elevated INR due to warfarin at the time of surgery had clinically significant bleeding. No major clinical events were attributed to bleeding complications. A total of 67 patients (33%) received a red blood cell transfusion during or immediately after the surgical procedure; platelet transfusions were administered to six patients. The transfusion requirements in relation to the anticoagulation/antiplatelet regimen are enumerated in Table 7 . There was no apparent association between transfusion requirements and time of discontinuation of antiplatelet and anticoagulant therapy. The majority of transfusions in patients receiving the dual antiplatelet regiment (aspirin and thienopyridine) were performed for blood loss that had occurred before surgery secondary to vascular complications related to the percutaneous coronary intervention, such as hematoma or pseudoaneurysm.
DISCUSSION
The most important finding of this study is that the risk of stent thrombosis and other major complications after noncardiac surgery is greatest in the first six weeks after stent placement and less thereafter, although due to the small number of events and the wide confidence intervals around these point estimates, the findings of this study should be regarded as suggestive and not definitive. The overall rate of complications was lower than in an earlier study of this issue (10) . Stent thrombosis. Stent thrombosis has been occurring less frequently in recent years than ever before, in part because of the combination therapy with both aspirin and a thienopyridine, and because of better understanding about how stents should be deployed (15) (16) (17) (18) . However, when stent thrombosis occurs, it usually results in either Q-wave MI or death (1, 8, 9) . Therefore, risk factors associated with stent thrombosis should be identified and steps taken to avoid this highly morbid complication. Effect of surgery on hemostasis. Surgery promotes thrombosis, and by its very nature requires thrombosis; all patients (19 -21) . These physiologic alterations that occur in the perioperative period may increase the risk of thrombosis of recently placed stents that might not have had the opportunity to re-endothelialize. Placement of a coronary stent results in complete denudation of the endothelial surface; re-endothelialization is believed to take place within approximately eight weeks (22, 23) . It is interesting to note that among patients who receive stents and who do not undergo surgery, the highest risk of stent thrombosis is within the first few hours and days after stent placement, and that even just two weeks of therapy with a thienopyridine is associated with a very low rate of stent thrombosis after the thienopyridine is discontinued (24) . Therefore, it is likely that partial endothelialization reduces the risk of stent thrombosis. Earlier studies. Current recommendations are that revascularization be reserved for patients in whom an indication for revascularization otherwise exists; it is unusual that revascularization needs to be performed to "get a patient through" his or her surgical procedure (25) . However, there are few data about the most appropriate duration that should elapse after percutaneous revascularization prior to surgery. In the only study of the issue that has been reported, Kaluza et al. (10) studied 40 patients and found that among those who underwent surgery within two weeks of stent placement the mortality rate was 32%. In contrast, there were no deaths, MIs, or episodes of stent thrombosis among the patients in whom Ͼ2 weeks elapsed before surgery. The current study. The current study is much larger and confirms an increased risk of major adverse events among patients in whom surgery is performed early after stent placement. However, we found that the increased risk persists for six weeks; there were no major adverse events among the patients in our study who underwent surgery Ͼ6 weeks after stent placement (0%, 95% confidence interval [CI] 0.0 to 9.0). We believe that our results are consistent with the time course of re-endothelialization of coronary arteries after stent placement. It should also be noted that the increased risk of adverse events following surgery was much lower than the 32% mortality in the previously published study (10) . In situations where non-cardiac surgery is fairly urgent, our study would suggest that the risk of major adverse cardiac events is fairly low even when surgery occurs prior to six weeks post stent placement (4.8%, 95% CI 2.1 to 9.2). This is similar to the low perioperative event rate previously reported from our institution following balloon angioplasty (26) . The risk of increased surgical bleeding is an important issue in patients undergoing non-cardiac surgery after coronary stent placement because of the potent antiplatelet agents administered to such patients, including aspirin and a thienopyridine (generally clopidogrel). These agents exert their antiplatelet effects via different mechanisms, but both aspirin and thienopyridines result in irreversible inhibition of platelet function and prolongation of the bleeding time.
The recovery of platelet function occurs from 7 to 10 days after the discontinuation of treatment (27) . We were not able to identify a relationship between the incidences of surgical bleeding in patients receiving a single antiplatelet agent, dual antiplatelet therapy, and no antiplatelet regiment; furthermore, transfusion requirements were similar in these groups. This was probably due to the relatively small number of patients in our study, the many different kinds of surgical procedures performed with greatly varying risks of bleeding, and the inescapable bias that patients undergoing surgical procedures associated with a greater risk of bleeding more frequently discontinued antiplatelet therapy prior to the surgical procedure, a bias that could not be eliminated in this study. However, a large prospective study confirmed the results of smaller retrospective studies indicating that there is a clear relationship between perioperative bleeding and administration of a thienopyridine shortly before or at the time of surgery (28 -31) . Our data clearly indicate that the risk of stent thrombosis and other complications is increased when surgery is performed within six weeks after stent placement and that, when possible, surgical procedures ought be delayed for at least six weeks following stent placement. Delaying surgery will not only allow completion of a full course of thienopyridine after stent placement, which has been shown to reduce the frequency of stent thrombosis, but will also allow for the subsequent recovery of platelet function, which probably does reduce the risk of perioperative bleeding even though it could not be demonstrated in this study (28 -31) . It should be noted that the frequency of stent thrombosis following surgery may be different following coronary brachytherapy, because the time course of endothelialization of the stent is delayed in this setting (32) .
Finally, we should also mention that some investigators have proposed the use of heparin-coated stents for the prevention of early thrombotic occlusion. The results of the Aspirin Alone Antiplatelet Regimen After Intracoronary Placement of the Carbostent (ANTARES) study suggest low rates of stent thrombosis (33) . These results are supported by the findings of Vrolix et al. but do not differ significantly from recent data suggesting that stent thrombosis rates continue to decline (34, 35) . No randomized controlled data support the use of heparin-coated stents for the prevention of stent thrombosis in general, or for preoperative coronary stenting in particular (36) . Study limitations. This retrospective study is subject to the limitations of all such studies. However, two limitations deserve special emphasis. Our ability to determine a relationship between time to surgery and bleeding, and the impact of adjunctive antiplatelet and anticoagulant therapy, are severely limited in this study, as previously described. Therefore, analysis of the relationship between bleeding and transfusion requirements on the one hand and antiplatelet and anticoagulant therapy on the other should be interpreted with great caution. Similarly, identification of additional covariates of stent thrombosis and clinical outcomes is limited because there were few clinical events. Specifically, there is a risk of "overfitting" (modeling idiosyncracies in the sample that may not generalize to other populations) if there are fewer than 10 events per covariate (37) . The second important limitation relates to the possibility that "sicker" patients had to proceed to surgery more rapidly and that delaying surgery could not be expected to eliminate all adverse events. Conclusions. Nonetheless, we conclude that delaying surgery for up to six weeks after completing a course of therapy with a thienopyridine is associated with a lower frequency of stent thrombosis and other adverse events. 
